Details for Patent: 11,712,442
✉ Email this page to a colleague
Which drugs does patent 11,712,442 protect, and when does it expire?
Patent 11,712,442 protects YUTREPIA and is included in one NDA.
This patent has twelve patent family members in six countries.
Summary for Patent: 11,712,442
| Title: | Dry powder treprostinil for the treatment of pulmonary hypertension |
| Abstract: | A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil. |
| Inventor(s): | Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor |
| Assignee: | Liquidia Technologies Inc |
| Application Number: | US17/104,348 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,712,442
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Tech | YUTREPIA | treprostinil sodium | POWDER;INHALATION | 213005-001 | May 23, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE | ⤷ Start Trial | ||||
| Liquidia Tech | YUTREPIA | treprostinil sodium | POWDER;INHALATION | 213005-002 | May 23, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE | ⤷ Start Trial | ||||
| Liquidia Tech | YUTREPIA | treprostinil sodium | POWDER;INHALATION | 213005-003 | May 23, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,712,442
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017261317 | ⤷ Start Trial | |||
| Australia | 2023201307 | ⤷ Start Trial | |||
| Australia | 2025204321 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
